Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
66.84
-0.26 (-0.39%)
At close: Sep 21, 2026, 4:00 PM EDT
67.30
+0.46 (0.69%)
After-hours: Sep 21, 2026, 7:37 PM EDT
Nektar Therapeutics Employees
Nektar Therapeutics had 63 employees as of December 31, 2025. The number of employees increased by 2 or 3.28% compared to the previous year.
Employees
63
Change (1Y)
2
Growth (1Y)
3.28%
Revenue / Employee
$866,492
Profits / Employee
-$2,494,079
Market Cap
2.28B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 2 | 3.28% |
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Vera Therapeutics | 361 |
| Ocular Therapeutix | 325 |
| UroGen Pharma | 300 |
| Harmony Biosciences Holdings | 293 |
| Aurinia Pharmaceuticals | 128 |
| Mineralys Therapeutics | 76 |
| Trevi Therapeutics | 34 |
NKTR News
- 24 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 27 days ago - Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 5 weeks ago - Nektar Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Nektar Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Nektar Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Nektar Therapeutics Announces Second Quarter 2026 Financial Results - PRNewsWire
- 7 weeks ago - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PRNewsWire